Cyplasin selects Aurobindo Pharma to supply API component for Ribavirin drug

Cyplasin Biomedical (CPBM: OTCBB and XYI1:FRA) is a product-oriented, specialty pharmaceutical company focused on developing products for the multi-billion dollar hepatitis C virus (HCV) market. The Company is pleased to announce that it has selected Aurobindo Pharma located in Hyderabad , India to supply  the active pharmaceutical ingredient (API) component for its Ribavirin drug product called C-Virin. 

The Company has ordered an initial  amount of the  Ribavirin API  in order to develop various formulations of its C-Virin product and initiate next step  product development activities .

Cyplasin CEO Garth Likes commented, "We are pleased to be able to work with such a high quality company as Aurobindo as this initiates the next step of our overall product development strategy.  We are working closely with our partners to expedite the Ribavirin API produced by Aurobindo so to formulate it into the final commercial form of the C-Virin product, thus bringing us that much closer to  revenue generation."




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Early clinical trial data in for whole virus COVID-19 vaccine candidate